@VergentBio profile picture
Vergent Bioscience @VergentBio

Vergent Bioscience / @VergentBio / Tumor-targeted agents to help surgeons realize the full potential of minimally invasive and robotic-assisted cancer surgery

Joined February 2015
  • Tweets 127
  • Following 185
  • Followers 162
43 Photos and videos
Vergent Bioscience names Adam Gridley President & CEO. John Santini, PhD, moves to CTO to lead platform expansion as we advance a Phase 3 study evaluating abenacianine for tumor visualization during lung cancer surgery. Read more: bit.ly/43kDXu7 #Leadership
1
1
3
61
#News: Vergent Bioscience has initiated VISUALIZE 2, a Phase 3 pivotal study evaluating abenacianine (VGT-309) for tumor visualization during lung cancer surgery. Read more: bit.ly/4lB9aS0 #OncologyInnovation #ClinicalResearch
1
1
1
220
Following #ASCO25, CEO @JSantini1 spoke with ONCOLife to discuss how abenacianine (VGT-309) is shining a light on #lungcancersurgery. ▶️ Watch: bit.ly/44M9vJv #Innovation #OncologyInnovation #Biotech #ThoracicSurgery
1
2
115
#News: Phase 2B VISUALIZE study results will be presented by @PennMedicine’s Dr. Sunil Singhal at #ASCO25, demonstrating that intraoperative molecular imaging with abenacianine for injection (VGT-309) during lung surgery has the potential to improve surgical outcomes. More: bit.ly/439aILt
1
2
194
#News: @PennMedicine’s Dr. Sunil Singhal will present new data from Vergent Bioscience on abenacianine (VGT-309) at #ASCO25, showcasing advances in tumor visualization with the potential to transform how surgeons identify and remove cancerous tissue. bit.ly/4jQ326I
62
Our CEO @JSantini1recently chatted with @MedTechGurus about Vergent’s mission and efforts to help surgeons unlock the full potential of minimally invasive and robotic-assisted surgery by making tumors easier to see. Learn more: bit.ly/3Y6hZZK #LCAM #Innovation

Med Tech Gurus: Tell The Story in A Compelling Way

Welcome Med Tech Gurus, You are in for a treat In this episode we're honored to have Dr. John Santini, President & CEO of , as our guest. Dr. Santini, recognized as one of Popular Science's "Brilli...

med-tech-gurus.libsyn.com
38
We were honored to join the 5th International Sublobar Resections & Bronchoscopic Ablation Summit last week in Paris! Engaging with global experts who are advancing #LungCancer care through innovation inspires us to continue working toward better surgical outcomes. #InnovationInMedicine
1
53
#NEWS: Vergent has received Fast Track designation from the @US_FDA for our novel, investigational tumor-targeted fluorescent imaging agent. Read more: bit.ly/4j3ZEFm #meded #lungcancer
785
Vergent is a proud sponsor of the 5th International Sublobar Resections and Bronchoscopic Ablation Summit, taking place January 9 & 10 in #Paris. We’re looking forward to connecting with global leaders and exploring the latest in surgical #innovation.
47
#DYK when #lungcancer is caught early, surgery can be an effective treatment? Our mission is to make #cancer surgery more successful by enhancing #tumorvisualization during surgery. Learn more in this recent @MedTechGurus episode: bit.ly/3Y6hZZK #Innovation
0:28
50
Approximately every 2.5 minutes, someone in the U.S. is diagnosed with lung cancer. During #LungCancerAwarenessMonth, we join the community in raising awareness of #LungCancer as one of the most common and deadly cancers. Learn more about our work: vergentbio.com/technology
3
44
We’ve completed patient enrollment in our Phase 2 VISUALIZE trial evaluating the potential of our novel, investigational tumor-targeted fluorescent imaging agent to improve tumor visualization during lung cancer surgery. Learn more: vergentbio.com/news-2024-nov… #clinicaltrials
43
At @WMISWMIC next week, @PennMedicine’s Dr. Sunil Singhal will share clinical research that shows how enhanced tumor visualization may benefit surgeons and patients during #lungcancer surgery. Learn more here: bit.ly/4e1KZHw #WMIC2024 #tumorvisualization #meded #MedX
2
7
2,561
Phase 2 data published in @STS_CTsurgery journal @annalsthorsurg show VGT-309 may help surgeons see difficult-to-find and previously undetected tumors in real-time during #MIS and robotic-assisted surgery. bit.ly/4bNYCIE #TumorVisualization #LungCancer
0:08
5
5
3,859
CEO @JSantini1 spoke with ONCOLife about our investigational advanced imaging agent, VGT-309. See how we’re enhancing tumor visualization & creating the potential to make cancer surgery more successful for both surgeons & patients. healthandpharma.net/oncolife (p42) #MedEd #Biotech
0:19
1
94
We're excited to welcome Alix Alderman to our #leadership team! A renowned global regulatory professional, her more than 20 years of drug development experience will help drive our mission to reimagine tumor visualization. bit.ly/49VZnyp #BioTech #TeamVergent
51
Thanks to @9NewsMelb for highlighting our study of VGT-309 with @StVincentsMelb, as we aim to help surgeons see difficult-to-find tumors in real time during surgery. Check out the story below! #lungcancer #innovation @msanto92
9News Melbourne
@9NewsMelb
3 Feb 2024
There's hope surgeons will soon be able to find and remove cancers with greater accuracy. A molecule is being tested in Melbourne which makes tumours glow green under infrared light. @msanto92 #9News
2:08
3
7
1,883
New data presented at the 60th Annual Meeting of the Society of Thoracic Surgeons demonstrate that VGT-309 helps surgeons visualize primary and metastatic tumor tissue in the lung during surgery. Learn more: vergentbio.com/vergent-prese… #STS2024 @STS_CTsurgery #lungcancer
4
7
1,256
#NEWS: The first patients have been enrolled in our Phase 2 multi-center VISUALIZE study! The study will assess the potential of our tumor-targeted fluorescent imaging agent, VGT-309, to improve visibility of tumors during lung cancer surgery. Read more: vergentbio.com/vergent-bio-i… #clinicaltrials #medtwitter #meded
2
5
1,011
#Didyouknow early-stage #lungcancer can usually be treated with surgery intended to completely remove the cancer leading to a cure? Learn more about our VGT-309 technology: vergentbio.com/focus #LungCancerAwarenessMonth
1
1
86
Load more